| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | METHODS OF TREATING HEMOGLOBINOPATHIES | US14646284 | 2013-11-20 | US20150265684A1 | 2015-09-24 | Rahima Zennadi |
| Methods of alleviating the symptoms of hemoglobinopathies, including, but not limited to, sickle cell disease, β-thalassemia, and hemoglobin H disease are provided. In some embodiments, the methods comprise administering an inhibitor selected from a β-arrestin1/2 inhibitor and/or a GRK2 inhibitor to the subject. Methods of inhibiting adhesion of sickle red blood cells to endothelial cells and adhesion to and activation of leukocytes are also provided. | ||||||
| 2 | Methods of treating hemoglobinopathies | US14646284 | 2013-11-20 | US09861685B2 | 2018-01-09 | Rahima Zennadi |
| Methods of alleviating the symptoms of hemoglobinopathies, including, but not limited to, sickle cell disease, β-thalassemia, and hemoglobin H disease are provided. In some embodiments, the methods comprise administering an inhibitor selected from a β-arrestin1/2 inhibitor and/or a GRK2 inhibitor to the subject. Methods of inhibiting adhesion of sickle red blood cells to endothelial cells and adhesion to and activation of leukocytes are also provided. | ||||||
| 3 | MOLECULAR TARGETS AND COMPOUNDS, AND METHODS TO IDENTIFY THE SAME, USEFUL IN THE TREATMENT OF DISEASES ASSOCIATED WITH EPITHELIAL MESENCHYMAL TRANSITION | US14775861 | 2014-03-07 | US20160003808A1 | 2016-01-07 | Richard Antonius Jozef Janssen; Annemarie Nicolete Lekkerkerker; Jamil Aarbiou |
| The present invention relates to methods and assays for identifying agents useful in the treatment of diseases associated with epithelial mesenchymal transition (EMT), in particular fibrotic diseases and cancer. The invention provides polypeptide and nucleic acid TARGETs, siRNA sequences based on these TARGETs and antibodies against the TARGETs. The invention is further related to pharmaceutical composition comprising siRNA sequences based on the TARGETs and antibodies against the TARGETs for use in the treatment of diseases associated with epithelial mesenchymal transition, in particular fibrotic disease and cancer. The invention further provides in vitro methods for inhibition of epithelial mesenchymal transition. | ||||||
| 4 | 上皮間葉移行に関連した疾患の治療において有用な分子標的及び前記標的のインヒビター | JP2015562043 | 2014-03-07 | JP2016522675A | 2016-08-04 | アントニウス ジョゼフ ジャンセン リチャード; ニコレテ レケルケルケル アンマリ; アルビオウ ジャミル |
| 本発明は、上皮間葉移行(EMT)に関連した疾患、特に線維症及び癌の治療において有用な物質を同定する方法及びアッセイに関する。本発明は、ポリペプチド及び核酸標的物、これらの標的物を基にしたsiRNA配列及び標的物に対する抗体を提供する。本発明は更に、上皮間葉移行に関連した疾患、特に線維症及び癌の治療における使用のための、標的物を基にしたsiRNA配列及び標的物に対する抗体を含有する医薬組成物に関する。本発明は更に、上皮間葉移行を阻害するインビトロ方法を提供する。【選択図】なし | ||||||
| 5 | MOLECULAR TARGETS AND COMPOUNDS, AND METHODS TO IDENTIFY THE SAME, USEFUL IN THE TREATMENT OF DISEASES ASSOCIATED WITH EPITHELIAL MESENCHYMAL TRANSITION | EP14708867.8 | 2014-03-07 | EP2972381A2 | 2016-01-20 | JANSSEN, Richard Antonius Jozef; LEKKERKERKER, Annemarie Nicolette; AARBIOU, Jamil |
| The present invention relates to methods and assays for identifying agents useful in the treatment of diseases associated with epithelial mesenchymal transition(EMT), in particular fibrotic diseases and cancer. The invention provides polypeptide and nucleic acid TARGETs, siRNA sequences based on these TARGETs and antibodies against the TARGETs. The invention is further related to pharmaceutical composition comprising siRNA sequences based on the TARGETs and antibodies against the TARGETs for use in the treatment of diseases associated withepithelial mesenchymal transition, in particular fibrotic disease and cancer. The invention further provides in vitro methods for inhibition of epithelial mesenchymal transition. | ||||||
| 6 | MOLECULAR TARGETS AND COMPOUNDS, AND METHODS TO IDENTIFY THE SAME, USEFUL IN THE TREATMENT OF DISEASES ASSOCIATED WITH EPITHELIAL MESENCHYMAL TRANSITION | PCT/EP2014054443 | 2014-03-07 | WO2014139885A2 | 2014-09-18 | JANSSEN RICHARD ANTONIUS JOZEF; LEKKERKERKER ANNEMARIE NICOLETTE; AARBIOU JAMIL |
| The present invention relates to methods and assays for identifying agents useful in the treatment of diseases associated with epithelial mesenchymal transition(EMT), in particular fibrotic diseases and cancer. The invention provides polypeptide and nucleic acid TARGETs, siRNA sequences based on these TARGETs and antibodies against the TARGETs. The invention is further related to pharmaceutical composition comprising siRNA sequences based on the TARGETs and antibodies against the TARGETs for use in the treatment of diseases associated withepithelial mesenchymal transition, in particular fibrotic disease and cancer. The invention further provides in vitro methods for inhibition of epithelial mesenchymal transition. | ||||||
QQ群二维码
意见反馈
意见反馈